SLC5A2 and diabetic kidney disease: SGLT2 inhibitors, such as dapagliflozin [27], canagliflozin [28] and empagliflozin [29], were initially developed to lower blood glucose concentrations but also showed very favorable protective effects in DKD apparently independent of the blood glucose lowering effect.